CN1311829C - 抑制由α4整合素介导的白细胞粘附的杂芳基化合物 - Google Patents

抑制由α4整合素介导的白细胞粘附的杂芳基化合物 Download PDF

Info

Publication number
CN1311829C
CN1311829C CNB038112582A CN03811258A CN1311829C CN 1311829 C CN1311829 C CN 1311829C CN B038112582 A CNB038112582 A CN B038112582A CN 03811258 A CN03811258 A CN 03811258A CN 1311829 C CN1311829 C CN 1311829C
Authority
CN
China
Prior art keywords
diethylamino
ylamino
pyrimidin
dimethylcarbamoyloxyphenyl
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038112582A
Other languages
English (en)
Chinese (zh)
Other versions
CN1652789A (zh
Inventor
安德烈·W·康拉迪
克里斯托夫·M·塞姆科
许英姿
弗兰克·斯塔潘贝克
布赖恩·P·斯图皮
珍妮弗·史密斯
尤金·D·托尔塞特
迈克尔·A·普莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of CN1652789A publication Critical patent/CN1652789A/zh
Application granted granted Critical
Publication of CN1311829C publication Critical patent/CN1311829C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038112582A 2002-05-24 2003-05-27 抑制由α4整合素介导的白细胞粘附的杂芳基化合物 Expired - Fee Related CN1311829C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38324402P 2002-05-24 2002-05-24
US60/383,244 2002-05-24

Publications (2)

Publication Number Publication Date
CN1652789A CN1652789A (zh) 2005-08-10
CN1311829C true CN1311829C (zh) 2007-04-25

Family

ID=29584533

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038112582A Expired - Fee Related CN1311829C (zh) 2002-05-24 2003-05-27 抑制由α4整合素介导的白细胞粘附的杂芳基化合物

Country Status (17)

Country Link
US (2) US7335663B2 (enExample)
EP (1) EP1507533B1 (enExample)
JP (1) JP4413135B2 (enExample)
CN (1) CN1311829C (enExample)
AT (1) ATE464298T1 (enExample)
AU (1) AU2003237302B8 (enExample)
BR (1) BR0309619A (enExample)
CA (1) CA2480756A1 (enExample)
DE (1) DE60332109D1 (enExample)
EA (1) EA008180B1 (enExample)
IL (1) IL164323A (enExample)
MX (1) MXPA04011657A (enExample)
NO (1) NO20045276L (enExample)
NZ (1) NZ535723A (enExample)
TW (1) TW200307671A (enExample)
WO (1) WO2003099231A2 (enExample)
ZA (1) ZA200407944B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045157A1 (zh) * 1999-01-22 2002-11-15 依兰制药公司 抑制vla-4介导的白细胞粘着的化合物
US20050074451A1 (en) * 2003-06-25 2005-04-07 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
JP2007528397A (ja) * 2004-03-10 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｖｌａ−４アンタゴニスト
CA2573245C (en) * 2004-07-08 2013-10-01 Elan Pharmaceuticals, Inc. Multivalent vla-4 antagonists comprising polymer moieties
WO2006023396A2 (en) * 2004-08-16 2006-03-02 Merck & Co., Inc. Vla-4 antagonists
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE493405T1 (de) * 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
EA017110B1 (ru) * 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) * 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
CA2708262A1 (en) * 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
SG10201401836RA (en) * 2009-04-27 2014-10-30 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
US8343706B2 (en) 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
HUE061244T2 (hu) 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CN111197057B (zh) * 2018-11-19 2024-04-19 中国科学院分子细胞科学卓越创新中心 调控免疫细胞迁移的组合物和方法
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (en) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute VLA proteins
CN1182746A (zh) * 1996-11-15 1998-05-27 赫彻斯特股份公司 用作白细胞粘合抑制剂和vla-4拮抗剂的新的杂环化合物
CN1201454A (zh) * 1995-08-30 1998-12-09 G·D·瑟尔公司 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4046876A (en) * 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4073914A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) * 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
JPS5727454B2 (enExample) * 1975-02-21 1982-06-10
CA1102316A (en) 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4036955A (en) * 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018913A (en) * 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) * 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) * 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) * 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4565814A (en) 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) * 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
PH22520A (en) * 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) * 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
DE3904931A1 (de) * 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) * 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) * 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) * 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
WO1992016549A1 (de) 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
IT1247509B (it) * 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
BR9306058A (pt) * 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
DE4227748A1 (de) * 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (en) 1994-07-11 2003-04-16 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
PT765879E (pt) * 1995-09-29 2001-05-31 Sankyo Co Derivados 13-substituidos de milbemicina-5-oxima sua preparacao e utilizacao contra insectos e outras pragas
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
US6211333B1 (en) 1996-06-21 2001-04-03 Takeda Chemical Industries, Ltd. Method for producing peptides and their salts which have an agonist activity of luteinizing hormone releasing hormones secreted from the hypothalamus
EP0907637A1 (de) 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647317A1 (de) * 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
NZ334950A (en) 1996-11-22 2001-03-30 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters and pharmaceutical compositions comprising same; useful for inhibiting beta-amyloid peptide release and/or its synthesis
AU6264898A (en) 1997-02-04 1998-08-25 Versicor Inc Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
IL133640A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
IL133641A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
PL338373A1 (en) 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
ATE260243T1 (de) 1997-08-22 2004-03-15 Hoffmann La Roche N-aroylphenylalaninderivate
KR100554815B1 (ko) 1997-08-22 2006-02-22 에프. 호프만-라 로슈 아게 엔-아로일페닐알라닌 유도체
CN1294576A (zh) 1998-01-23 2001-05-09 诺瓦提斯公司 Vla－4拮抗剂
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
KR20010042614A (ko) 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
HK1045157A1 (zh) * 1999-01-22 2002-11-15 依兰制药公司 抑制vla-4介导的白细胞粘着的化合物
WO2000043369A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (en) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute VLA proteins
CN1201454A (zh) * 1995-08-30 1998-12-09 G·D·瑟尔公司 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂
CN1182746A (zh) * 1996-11-15 1998-05-27 赫彻斯特股份公司 用作白细胞粘合抑制剂和vla-4拮抗剂的新的杂环化合物

Also Published As

Publication number Publication date
US20050130999A1 (en) 2005-06-16
EP1507533A4 (en) 2007-05-23
EA200401561A1 (ru) 2005-06-30
AU2003237302B8 (en) 2008-04-03
IL164323A0 (en) 2005-12-18
TW200307671A (en) 2003-12-16
US20040142954A1 (en) 2004-07-22
ZA200407944B (en) 2006-07-26
AU2003237302A1 (en) 2003-12-12
CN1652789A (zh) 2005-08-10
AU2003237302B2 (en) 2008-03-06
EP1507533B1 (en) 2010-04-14
CA2480756A1 (en) 2003-12-04
US7008949B2 (en) 2006-03-07
MXPA04011657A (es) 2005-08-18
IL164323A (en) 2010-02-17
EA008180B1 (ru) 2007-04-27
BR0309619A (pt) 2005-06-28
NO20045276L (no) 2004-12-01
WO2003099231A3 (en) 2004-01-22
JP2005529155A (ja) 2005-09-29
DE60332109D1 (de) 2010-05-27
EP1507533A2 (en) 2005-02-23
JP4413135B2 (ja) 2010-02-10
ATE464298T1 (de) 2010-04-15
NZ535723A (en) 2005-08-26
US7335663B2 (en) 2008-02-26
WO2003099231A2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2003237302B8 (en) Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
US7427628B2 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
CN101389611B (zh) 抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物
HK1072608B (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
KR20050018680A (ko) 알파-4 인테그린에 의해 매개되는 백혈구 부착 저해헤테로아릴 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070425

Termination date: 20110527